News Archive
Dr. David Diemert, director of The GW Vaccine Research Unit, was interviewed on CTV Your Morning about our current clinical trial of an experimental HIV vaccine.
“The future implications are huge if we could have an effective HIV vaccine that would prevent people from getting the…
George Washington University has collaborated with Moderna to test the safety of the first mRNA HIV vaccines and the immune responses of two participants in the Phase 1 clinical trial. Four institutions, including GW, have enrolled 56 HIV-negative adult participants for the vaccines’ clinical…
The George Washington University is one of four US sites conducting a Phase I clinical trial to test the safety and immune responses of two mRNA vaccine antigens for HIV on 56 healthy adults. The GW Vaccine Research Unit is running one of the study sites and acting as the processing lab and…
IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C…
The Delta variant of the SARS-CoV-2 virus is causing a surge in COVID-19 cases globally, including in the United States, where there has been a sharp increase in reported cases. The Clinical Director of the GW Vaccine Research Unit, Dr. David Diemer, discusses the Delta Variant and the Fourth…
A vaccine for Lassa fever may be on the horizon, thanks to a new clinical trial jointly led by Elissa Malkin, DO, MPH, assistant research professor of medicine at the George Washington University School of Medicine and Health Sciences. With an award from trial sponsor IAVI, Malkin, along with…
The same system Moderna used for its COVID vaccine may also be able to help prevent HIV. Two of Moderna’s mRNA-based HIV vaccines could start human trials this week, according to a new posting in the National Institutes of Health’s clinical trial registry. The Phase I study would test the…
GW will be a clinical trial site for Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Multidisciplinary effort boosts the George Washington University COVID-19 vaccine clinical trial. And when it comes to enrollment successes, Magnus points to GW's storied history in forming bonds with the local community. "The context of the HIV Prevention Network is so important and the…
A critical goal for the Phase 3 clinical trial is also to ensure that the pool of the vaccine test subjects reflects the nation’s diversity, including minorities, older Americans and people with preexisting health conditions. It’s all the more important given the disparate impact the pandemic…